Illumina shares fell 18.6% after earnings, despite Q3 results above company guidance and raised full-year outlook. The transcript does not identify a specific disappointment behind the selloff; it does flag continued weakness in research and applied consumables, while the outlook depends on stronger Q4 sequencing consumables revenue.
- Illumina placed over 80 NovaSeq X instruments in Q3, bringing placements to approximately 360 over the last four quarters.
- Rest-of-world clinical sequencing consumables grew 14%; research and applied consumables declined 6%. The company expects mid-teens clinical growth and mid- to high-single-digit declines in research and applied for 2026.
- Management raised full-year revenue, margin, and EPS outlooks, citing Q3 outperformance and stronger Q4 sequencing consumables revenue from a larger NovaSeq X installed base.
- The company expects second-half 2026 operating margins of approximately 25%, about 400 basis points above 2024.
- Tariff refunds boosted reported GAAP and non-GAAP operating income, margins, and EPS, while negatively affecting revenue; the financial measures discussed on the call excluded their impact.
Community Discussion